23:11 , Jun 7, 2018 |  BC Week In Review  |  Clinical News

Exact HCC assay significantly better than SOC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test. The test...
00:24 , Jun 6, 2018 |  BioCentury  |  Product Development

Second (Ex)act

Armed with Phase II data for its second DNA methylation test, Exact Sciences Corp. expects a repeat performance of the rapid launch trajectory its Cologuard colorectal cancer screening assay has enjoyed. Cologuard beat expectations for...
20:37 , Jun 5, 2018 |  BC Extra  |  Clinical News

Exact HCC assay significantly better than SOC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test. The test...
08:00 , Jan 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Homeobox A1 (HOXA1) In vitro and mouse studies suggest depleting...
07:00 , Jul 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Acid phosphatase 5 tartrate resistant (ACP5); fascin homolog 1 actin-bundling protein (FSCN1); homeobox A1 (HOXA1); heat shock...